CN1989146A - 硫酸化寡聚糖衍生物 - Google Patents

硫酸化寡聚糖衍生物 Download PDF

Info

Publication number
CN1989146A
CN1989146A CNA2005800068338A CN200580006833A CN1989146A CN 1989146 A CN1989146 A CN 1989146A CN A2005800068338 A CNA2005800068338 A CN A2005800068338A CN 200580006833 A CN200580006833 A CN 200580006833A CN 1989146 A CN1989146 A CN 1989146A
Authority
CN
China
Prior art keywords
compound
group
derivatives
mixture
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800068338A
Other languages
English (en)
Chinese (zh)
Inventor
V·费尔罗
J·K·法尔威瑟
T·卡洛丽
刘立功
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progen Industries Ltd
Original Assignee
Progen Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004901103A external-priority patent/AU2004901103A0/en
Application filed by Progen Industries Ltd filed Critical Progen Industries Ltd
Priority to CN201410042932.2A priority Critical patent/CN103788141B/zh
Publication of CN1989146A publication Critical patent/CN1989146A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
CNA2005800068338A 2004-03-04 2005-03-04 硫酸化寡聚糖衍生物 Pending CN1989146A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410042932.2A CN103788141B (zh) 2004-03-04 2005-03-04 硫酸化寡聚糖衍生物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004901103A AU2004901103A0 (en) 2004-03-04 Sulfated Oligosaccharide Derivatives
AU2004901103 2004-03-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201410353750.7A Division CN104119404A (zh) 2004-03-04 2005-03-04 硫酸化寡聚糖衍生物
CN201410042932.2A Division CN103788141B (zh) 2004-03-04 2005-03-04 硫酸化寡聚糖衍生物

Publications (1)

Publication Number Publication Date
CN1989146A true CN1989146A (zh) 2007-06-27

Family

ID=34916868

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA2005800068338A Pending CN1989146A (zh) 2004-03-04 2005-03-04 硫酸化寡聚糖衍生物
CN201410042932.2A Expired - Fee Related CN103788141B (zh) 2004-03-04 2005-03-04 硫酸化寡聚糖衍生物
CN201410353750.7A Pending CN104119404A (zh) 2004-03-04 2005-03-04 硫酸化寡聚糖衍生物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201410042932.2A Expired - Fee Related CN103788141B (zh) 2004-03-04 2005-03-04 硫酸化寡聚糖衍生物
CN201410353750.7A Pending CN104119404A (zh) 2004-03-04 2005-03-04 硫酸化寡聚糖衍生物

Country Status (17)

Country Link
US (2) US7875592B2 (enExample)
EP (1) EP1720889B1 (enExample)
JP (1) JP5139797B2 (enExample)
KR (1) KR101156273B1 (enExample)
CN (3) CN1989146A (enExample)
AU (1) AU2005219456B2 (enExample)
BR (1) BRPI0508144A (enExample)
CA (1) CA2557989C (enExample)
ES (1) ES2531880T3 (enExample)
HK (1) HK1199263A1 (enExample)
IL (1) IL177870A (enExample)
MX (1) MXPA06010049A (enExample)
NO (1) NO338461B1 (enExample)
RU (1) RU2392281C2 (enExample)
TW (1) TWI426080B (enExample)
WO (1) WO2005085264A1 (enExample)
ZA (1) ZA200607057B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101591401A (zh) * 2009-02-27 2009-12-02 江南大学 一种制备高活性低分子量肝素的方法
WO2012167434A1 (zh) * 2011-06-09 2012-12-13 基亚生物科技股份有限公司 用于抑制肝癌复发、恶化或转移之医药组成物
CN101874035B (zh) * 2007-10-16 2014-12-03 普罗吉恩制药有限公司 新的硫酸化寡糖衍生物
CN104876979A (zh) * 2015-06-19 2015-09-02 天津红日药业股份有限公司 一种新的具有抗Xa因子活性的磺酸化五糖化合物
CN105001278A (zh) * 2015-06-19 2015-10-28 天津红日药业股份有限公司 一种磺达肝癸钠二糖中间体片段的合成方法
CN105017341A (zh) * 2014-04-22 2015-11-04 华东师范大学 硫酸化岩藻-半乳四糖及其制备方法和应用
CN109069523A (zh) * 2016-12-10 2018-12-21 扬州蓝色生物医药科技有限公司 甘露寡聚糖类化合物及其作为抗rna病毒药物的应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2392281C2 (ru) * 2004-03-04 2010-06-20 Проджен Фармасьютикалз Лимитед Сульфатированные производные олигосахаридов
JP2008534519A (ja) * 2005-04-01 2008-08-28 クリストファー・リチャード・パリッシュ グルコサミンオリゴ糖などのｎｏｄ因子を用いる血管新生の調節
JP2011526925A (ja) * 2008-07-01 2011-10-20 ザカロン ファーマシューティカルズ，インク． ヘパラン硫酸阻害剤
EP2149580A1 (en) 2008-07-15 2010-02-03 Istituto Scientifico di Chimica E Biochimica "G Ronzoni Mimetics of sulfated oligosaccharides
JP5701498B2 (ja) * 2009-12-01 2015-04-15 公益財団法人微生物化学研究会 炎症性細胞からのヘパラナーゼの放出抑制剤、抗炎症剤、及び薬用組成物
EP3116887B1 (en) 2014-03-13 2021-02-17 Universität Basel Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein
JP6849667B2 (ja) 2015-09-16 2021-03-24 ウニヴェルズィテート バーゼル スフィンゴ糖脂質の糖鎖エピトープに対する抗体に結合する炭水化物リガンド
JP2016199579A (ja) * 2016-07-08 2016-12-01 基亜生物科技股▲ふん▼有限公司Ｍｅｄｉｇｅｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐ． 肝癌の再発、悪化または転移の抑制に用いる医薬組成物
JP2020503377A (ja) 2016-12-13 2020-01-30 ベータ セラピューティクス プロプライアタリー リミティド ヘパラナーゼ阻害剤及びそれの使用
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
WO2018107244A1 (en) 2016-12-15 2018-06-21 Progen Pg500 Series Pty Ltd Composition and uses thereof
US10842804B2 (en) * 2017-03-01 2020-11-24 Medigen Biotechnology Corporation Muparfostat for use in treating patients with hepatitis virus-related hepatocellular carcinoma after surgical resection
KR102377358B1 (ko) 2017-10-16 2022-03-23 삼성전자주식회사 반도체 메모리 소자 및 그 제조 방법
JP7359396B2 (ja) * 2017-12-15 2023-10-11 ジ・オーストラリアン・ナショナル・ユニヴァーシティ 細胞外ヒストンによって媒介される病理を処置及び予防するための化合物
JP6619830B2 (ja) * 2018-02-22 2019-12-11 基亜生物科技股▲ふん▼有限公司Ｍｅｄｉｇｅｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐ． 肝癌の再発、悪化または転移の抑制に用いる医薬組成物
CN109762032A (zh) * 2019-01-16 2019-05-17 天津科技大学 一种磺酸化路易斯x三糖及其合成方法和应用
SG11202109032SA (en) * 2019-02-25 2021-09-29 Univ Australian National Compounds for treating and preventing net associated complications
CN116813675B (zh) * 2023-08-23 2023-11-24 北京远大九和药业有限公司 一种化合物晶型及其制备、组合物和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003684A1 (fr) 1987-10-30 1989-05-05 Chugai Seiyaku Kabushiki Kaisha Agent anti-vih
FR2704226B1 (fr) * 1993-04-22 1995-07-21 Sanofi Elf 3-desoxy oligosaccharides, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5739115A (en) 1993-10-07 1998-04-14 Glycomed Incorporated Sulfated maltooligosaccharides with heparin-like properties
JPH09503510A (ja) * 1993-10-07 1997-04-08 グリコメド・インコーポレイテッド ヘパリン様特性を有する高硫酸化マルトオリゴ糖
AUPN261895A0 (en) 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
RU2193039C2 (ru) * 1995-04-28 2002-11-20 Такара Сузо Ко., Лтд. Соединение сахара
JPH09183789A (ja) * 1995-10-31 1997-07-15 Sanwa Kagaku Kenkyusho Co Ltd 新規な硫酸化及び燐酸化糖誘導体、その製法及び用途
IL120722A (en) * 1996-05-08 1999-07-14 Akzo Nobel Nv Polysulfated tetrasaccharide derivatives and pharmaceutical compositions containing them
AUPO556297A0 (en) 1997-03-11 1997-04-10 Australian National University, The Sulfated oligosaccharides having anticoagulant/ antithrombotic activity
IL126893A (en) * 1997-11-19 2003-05-29 Akzo Nobel Nv Sulfated pentasaccharide derivatives and pharmaceutical compositions containing them
FR2773801B1 (fr) * 1998-01-19 2000-05-12 Sanofi Sa Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant
CN1450075A (zh) * 2002-04-11 2003-10-22 中国科学院生态环境研究中心 一类寡糖及其硫酸化产物和它们的制备方法及含该寡糖的药物组合物
RU2392281C2 (ru) * 2004-03-04 2010-06-20 Проджен Фармасьютикалз Лимитед Сульфатированные производные олигосахаридов

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101874035B (zh) * 2007-10-16 2014-12-03 普罗吉恩制药有限公司 新的硫酸化寡糖衍生物
CN104666318A (zh) * 2007-10-16 2015-06-03 普罗吉恩制药有限公司 新的硫酸化寡糖衍生物
CN101591401A (zh) * 2009-02-27 2009-12-02 江南大学 一种制备高活性低分子量肝素的方法
WO2012167434A1 (zh) * 2011-06-09 2012-12-13 基亚生物科技股份有限公司 用于抑制肝癌复发、恶化或转移之医药组成物
CN103547270A (zh) * 2011-06-09 2014-01-29 基亚生物科技股份有限公司 用于抑制肝癌复发、恶化或转移之医药组成物
CN105017341A (zh) * 2014-04-22 2015-11-04 华东师范大学 硫酸化岩藻-半乳四糖及其制备方法和应用
CN105017341B (zh) * 2014-04-22 2018-05-15 华东师范大学 硫酸化岩藻-半乳四糖及其制备方法和应用
CN105001278A (zh) * 2015-06-19 2015-10-28 天津红日药业股份有限公司 一种磺达肝癸钠二糖中间体片段的合成方法
CN104876979A (zh) * 2015-06-19 2015-09-02 天津红日药业股份有限公司 一种新的具有抗Xa因子活性的磺酸化五糖化合物
CN105001278B (zh) * 2015-06-19 2018-07-06 天津红日药业股份有限公司 一种磺达肝癸钠二糖中间体片段的合成方法
CN104876979B (zh) * 2015-06-19 2018-10-09 天津红日药业股份有限公司 一种具有抗Xa因子活性的磺酸化五糖化合物
CN109069523A (zh) * 2016-12-10 2018-12-21 扬州蓝色生物医药科技有限公司 甘露寡聚糖类化合物及其作为抗rna病毒药物的应用
CN109069523B (zh) * 2016-12-10 2022-05-06 扬州蓝色生物医药科技有限公司 甘露寡聚糖类化合物及其作为抗rna病毒药物的应用

Also Published As

Publication number Publication date
US7875592B2 (en) 2011-01-25
BRPI0508144A (pt) 2007-07-24
WO2005085264A1 (en) 2005-09-15
AU2005219456B2 (en) 2011-04-07
CA2557989C (en) 2013-04-23
HK1199263A1 (en) 2015-06-26
US20110130354A1 (en) 2011-06-02
KR101156273B1 (ko) 2012-06-13
EP1720889B1 (en) 2014-11-26
CN103788141A (zh) 2014-05-14
NO338461B1 (no) 2016-08-15
TW200602351A (en) 2006-01-16
AU2005219456A1 (en) 2005-09-15
CN104119404A (zh) 2014-10-29
IL177870A (en) 2011-08-31
ZA200607057B (en) 2008-04-30
MXPA06010049A (es) 2007-04-10
JP5139797B2 (ja) 2013-02-06
RU2006134972A (ru) 2008-04-10
US20070185037A1 (en) 2007-08-09
NO20064489L (no) 2006-11-27
US8173606B2 (en) 2012-05-08
CN103788141B (zh) 2016-08-17
CA2557989A1 (en) 2005-09-15
EP1720889A4 (en) 2008-03-19
EP1720889A1 (en) 2006-11-15
TWI426080B (zh) 2014-02-11
IL177870A0 (en) 2006-12-31
ES2531880T3 (es) 2015-03-20
RU2392281C2 (ru) 2010-06-20
JP2007526257A (ja) 2007-09-13
KR20070007815A (ko) 2007-01-16

Similar Documents

Publication Publication Date Title
US8173606B2 (en) Sulfated oligosaccharide derivatives
CN101874035B (zh) 新的硫酸化寡糖衍生物
JP3345020B2 (ja) 合成ポリサッカライド、それらの製造法およびそれらを含む医薬組成物
CA2551181A1 (en) Glycosaminoglycan (gag) mimetics
Cai et al. Conformation-controlled hydrogen-bond-mediated aglycone delivery method for α-xylosylation
WO2008041131A2 (en) Anticoagulant compounds
HK1197915B (en) Sulfated oligosaccharide derivatives
HK1197915A (en) Sulfated oligosaccharide derivatives
HK1108581A (en) Sulfated oligosaccharide derivatives
HK1149564B (en) Novel sulfated oligosaccharide derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1108581

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20070627

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1108581

Country of ref document: HK